PepScribe
Category 2 · Educational only

Wolverine (BPC-157 / TB-500): what the research says. | Reddit

Last updated September 25, 2026

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

“Wolverine” is a community nickname for a compounded blend of two tissue-repair peptides, BPC-157 and TB-500, named for the fictional character’s rapid healing. Here’s what the evidence behind each component actually supports.

Regulatory notice: Wolverine (BPC-157 / TB-500) is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. Its status is in active transition: on July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to review BPC-157 and TB-500 for addition to the list. Any recommendation from that committee is non-binding, and FDA has not issued a final determination.

This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.

What the Wolverine blend is.

“Wolverine” is not a single molecule. It is a nickname the peptide community uses for a combination of two separate research peptides, BPC-157 and TB-500, prepared together. There is no standardized formula; the ratio and concentrations vary by source, which is one reason blend research is harder to interpret than single-peptide research.

BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in gastric juice, studied primarily for connective-tissue and gut healing. TB-500 refers to thymosin beta-4 (or its active LKKTETQ fragment), an actin-regulating peptide studied for cell migration and tissue repair. The rationale for combining them is that they are thought to support repair through complementary, non-overlapping mechanisms, but that rationale comes from the separate literature on each peptide, not from trials of the blend itself.

How the two components are studied.

BPC-157 · Angiogenesis

Blood-vessel formation

Brcic et al. (2009, J Physiol Pharmacol) reported that BPC-157 promoted angiogenesis in muscle and tendon healing in rat models. New blood vessels deliver oxygen and nutrients to injured tissue, a rate-limiting step in repair.

BPC-157 · Tendon & ligament

Tendon-to-bone healing

Krivic et al. (2006, J Orthop Res) found BPC-157 promoted tendon-to-bone healing and offset corticosteroid-impaired healing in a rat Achilles model. The connective-tissue findings are the most-cited part of the BPC-157 literature.

TB-500 · Cell migration

Actin regulation

Thymosin beta-4 is the primary actin-sequestering protein in mammalian cells. A 1999 Journal of Investigative Dermatology study showed it promotes migration of endothelial cells and keratinocytes to wound sites, a proposed driver of its repair effects.

TB-500 · Regeneration

Progenitor-cell activity

Bock-Marquette et al. (2004, Nature) demonstrated thymosin beta-4 activated cardiac progenitor cells and improved repair in mouse models of myocardial infarction, suggesting a role in regeneration over scarring.

These mechanisms come from preclinical and animal studies of each peptide on its own. There are no published human clinical trials of the combined “Wolverine” blend, and none of these mechanisms have been confirmed in large-scale human trials.

What the research suggests.

Both peptides are studied mainly in animal models of tissue repair. The blend itself has not been trialed. What follows describes the component evidence.

Musculoskeletal repair

BPC-157’s most-cited findings are in tendon, ligament, and muscle models; TB-500’s parent protein has shown improved muscle-fiber regeneration in rodent injury models. The overlap in target tissue is the usual rationale offered for combining them, though no head-to-head or combination trial supports an additive effect in humans.

Inflammation

Both peptides have preclinical reports of reduced inflammatory signaling at injury sites. For thymosin beta-4 this includes lowered TNF-alpha and IL-1beta in animal models. These are markers in preclinical systems, not clinical outcomes.

The blend caveat

Combining two peptides does not automatically combine their benefits. Interactions, relative dosing, and stability in a single preparation are not characterized in the literature. Anyone reading blend claims should treat them as extrapolation from single-peptide animal data.

Administration (research context).

In research and anecdotal use, both BPC-157 and TB-500 are administered by subcutaneous injection. TB-500 protocols often describe a twice-weekly loading phase followed by less frequent maintenance; BPC-157 is typically described as daily. There is no standardized human protocol for either peptide, and none for the combination.

This is research context, not prescribing guidance. The Wolverine blend is handled consultation-first, and this information should not be interpreted as a dosing recommendation.

Side effects & safety considerations.

Human safety data on both peptides is limited, and there is no safety data on the blend specifically.

Reported in anecdotal use

  • Headache
  • Nausea
  • Localized redness or irritation at the injection site
  • Temporary lethargy or fatigue

Limited human data

Neither BPC-157 nor TB-500 has completed large-scale human safety trials, and the combined preparation has none. Systemic safety information comes primarily from animal toxicology and self-reported use, which is a real limitation.

Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.

Legal status.

Neither BPC-157 nor TB-500 is an FDA-approved drug, and neither is currently on FDA’s 503A Bulks List. On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to review both for addition to that list; any recommendation is non-binding, and FDA has not issued a final determination.

The February 27, 2026 HHS announcement about potential peptide reclassification may affect these substances, but it has no legal force until formally published in the Federal Register. Products labeled as “Wolverine” sold by gray-market vendors are unregulated research chemicals without pharmaceutical-grade quality assurance.

Deep dives

More on BPC-157.

Research-backed articles covering specific topics in depth.

References

  1. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology (Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S) — PMID 20388964 (2009).
  2. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research (Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P) — PMID 16583442 (2006).
  3. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology (PubMed) (1999).
  4. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature (PubMed) (2004).
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food & Drug Administration (fda.gov) (2025).

What Reddit says

r/bpc_15738 points34 commentsMar 2025

Journaling my experience with BPC-157/TB-500 blend

The journal thread contains its own control failure: one commenter ran 250 mcg of BPC-157 three times daily for two weeks on a shoulder with no difference, and another, three weeks into the blend after ACL surgery, reports posterior knee soreness worsening. Neither peptide is FDA-approved or on FDA's 503A Bulks List, and every account here runs alongside surgery and physical therapy, where improvement is expected on its own schedule, so the blend cannot be credited from these reports.

Posted on Reddit

Talk to a clinician about what's available.

Talk to a PepScribe clinician about the goals behind the blend. A licensed clinician recommends therapies that fit.

Explore the Longevity programBack to The Peptide Library

Written by B.A. Utterback.

Educational information only. Not medical advice. Treatment decisions are made by a licensed physician.